BPC-157 + TB-500 Blend: Wolverine Stack
Two complementary healing peptides combined: BPC-157 for localised repair through angiogenesis, TB-500 for systemic cell migration.
Quick Reference
| Composition | 5mg BPC-157 + 5mg TB-500 (10mg total) |
|---|---|
| Research Dosage | 250-500mcg of each peptide daily (500mcg-1mg total) |
| Frequency | Once or twice daily |
| Administration | Subcutaneous injection |
| Cycle Length | 6-8 weeks typical |
| Reconstitution | 2-3mL bacteriostatic water |
| Storage | Refrigerate after reconstitution, use within 4-6 weeks |
This blend combines two of the most extensively researched healing peptides into a single vial, creating what the research community commonly calls the "Wolverine Stack." BPC-157 and TB-500 work through entirely different mechanisms – BPC-157 targets localised tissue repair through angiogenesis and growth factor modulation, while TB-500 works systemically to enhance cell migration throughout the body.
The combination is named after the X-Men character known for rapid healing, reflecting the enhanced regenerative effects achieved through dual-pathway activation. Rather than two peptides doing similar things, BPC-157 and TB-500 address different phases of the healing cascade, potentially producing synergistic effects exceeding what either achieves alone.
Why Combine BPC-157 and TB-500?
The rationale for combination research is based on the fundamentally different but complementary mechanisms of these two peptides:
BPC-157: The Repair Program
BPC-157 (Body Protection Compound-157) acts primarily at the injury site to activate cellular repair processes:
Primary Mechanisms:
- VEGFR2 upregulation promoting angiogenesis (new blood vessel formation)
- Nitric oxide system modulation affecting blood flow and tissue protection
- Growth factor modulation (EGF, FGF, NGF, and others)
- FAK-paxillin pathway activation for cell adhesion and migration
- Gene expression changes favouring repair over inflammation
Key Characteristics:
- Strongest effects are localised to the injury area
- Promotes the actual repair "program" at cellular level
- Establishes blood supply to healing tissue
- Stable in gastric acid (unusual for peptides)
- Shorter half-life requiring daily administration
TB-500: The Delivery System
TB-500 (Thymosin Beta-4 fragment) works systemically to move repair cells throughout the body:
Primary Mechanisms:
- Actin regulation controlling cell structure and movement
- G-actin sequestration allowing increased cell fluidity
- Enhanced migration of fibroblasts, endothelial cells, and stem cells
- Anti-inflammatory effects (reduced cytokines, modulated macrophages)
- Direct promotion of angiogenesis through endothelial cell migration
Key Characteristics:
- Inherently systemic distribution throughout the body
- Facilitates cell migration to injury sites anywhere
- Longer biological half-life supporting less frequent dosing
- Acts on the "delivery" of repair cells rather than the repair program itself
The Synergy: How They Work Together
When used together, these peptides address multiple phases of the healing cascade:
- Cell Recruitment (TB-500): Mobilises repair cells (fibroblasts, endothelial cells, stem cells) and promotes their migration toward injury signals throughout the body
- Blood Supply Establishment (BPC-157): Creates new blood vessels to supply oxygen and nutrients to healing tissue – critical for injuries in areas with poor circulation like tendons
- Repair Activation (BPC-157): Activates growth factor cascades and cellular repair programs at the injury site
- Inflammation Modulation (Both): Both peptides reduce excessive inflammation while allowing necessary immune responses
- Tissue Remodelling (Both): Both contribute to organised tissue repair rather than disorganised scar formation
Why This Matters:
Many tissues (particularly tendons, ligaments, and cartilage) heal poorly because they lack adequate blood supply. BPC-157 addresses this through angiogenesis, while TB-500 ensures repair cells can actually reach the area. The combination attacks the problem from multiple angles simultaneously.
Research Applications
The BPC-157 + TB-500 combination is studied for comprehensive tissue repair across multiple systems:
Musculoskeletal Injuries
- Accelerated healing of tendons, ligaments, and muscles
- Reduced fibrosis and scar tissue formation
- Improved structural integrity of healed tissue
- Enhanced recovery from surgical procedures
- Joint injury and inflammation research
Wound Healing
- Faster wound closure
- Improved tissue remodelling
- Reduced scarring with better cosmetic outcomes
- Diabetic wound healing models (where healing is impaired)
Gastrointestinal Applications
- Gut repair and intestinal barrier restoration
- Protection against NSAID-induced damage
- Inflammatory bowel condition research
- Surgical anastomosis healing
Recovery Applications
- Post-surgical recovery acceleration
- Sports injury research
- Chronic injury and overuse conditions
- General tissue regeneration studies
Dosage Information
Research Dosages
Dosages commonly referenced in literature for the combination:
BPC-157 Component: 250-500mcg per day
TB-500 Component: 250-500mcg per day (when dosed daily from blend)
Total Daily Dose: 500mcg-1mg of the blend
Dosing Approaches
Daily Dosing (Most Common for Blend):
The pre-blended format is typically used with daily dosing:
- 250-500mcg of each peptide per day
- Once or twice daily administration
- Consistent tissue levels of both compounds
Split Dosing:
Some protocols split the daily dose:
- Morning: 250mcg each (500mcg total)
- Evening: 250mcg each (500mcg total)
Cycle Duration
Research protocols typically run 6-8 weeks, followed by an equal break period. This duration allows:
- Full tissue repair cycle completion
- Assessment of results
- Prevention of any potential tolerance development (precautionary)
Administration Site
Unlike using TB-500 alone (where injection site doesn't matter), the combination may benefit from injection proximal to the injury site to maximise BPC-157's local effects while TB-500 distributes systemically regardless.
For general or multiple issues, abdominal subcutaneous injection is commonly used.
Reconstitution Guide
Required Materials
- BPC-157 + TB-500 blend vial (10mg total: 5mg each)
- Bacteriostatic water (water containing 0.9% benzyl alcohol)
- Sterile insulin syringe for reconstitution
- Alcohol swabs for sterile technique
Reconstitution Steps
- Allow the vial to reach room temperature before reconstitution
- Draw 2-3mL of bacteriostatic water into the syringe
- Insert needle into vial and direct stream down inside wall – do not spray directly onto powder
- Allow powder to dissolve without shaking. Gentle swirling is acceptable. Both peptides dissolve readily.
- Store immediately refrigerated at 2-8°C
Concentration Reference Table
| Water Added | Total Concentration | Each Peptide | 500mcg Total Dose | 1mg Total Dose |
|---|---|---|---|---|
| 2mL | 5mg/mL | 2.5mg/mL each | 10 units (0.1mL) | 20 units (0.2mL) |
| 3mL | 3.33mg/mL | 1.67mg/mL each | 15 units (0.15mL) | 30 units (0.3mL) |
Storage Guidelines
Lyophilised (Powder) Form
- Stable at room temperature for weeks without significant degradation
- Refrigeration (2-8°C) extends stability to 6+ months
- Freezing (-20°C) extends stability to 12+ months
- Protect from light and moisture
- Keep vial sealed until ready for reconstitution
Reconstituted Solution
- Must be refrigerated at 2-8°C
- Stable for 4-6 weeks when stored correctly
- Do not freeze after reconstitution – freezing can damage the peptide structure
- Avoid repeated temperature fluctuations
- Use sterile technique when drawing doses to prevent contamination
- If solution becomes cloudy or contains particles, discard and reconstitute a fresh vial
Frequently Asked Questions
Common questions about BPC-157 + TB-500 Blend research
What is the Wolverine Stack?
The "Wolverine Stack" refers to the combination of BPC-157 and TB-500, named after the X-Men character known for rapid healing. The name reflects the combination's reputation for enhanced tissue repair through complementary mechanisms – BPC-157 activates repair processes while TB-500 delivers repair cells to injury sites.
Why use a pre-blended product instead of separate peptides?
Pre-blended products offer several advantages: accurate 1:1 ratios ensuring consistent dosing between peptides, single reconstitution instead of two separate vials reducing handling steps, reduced contamination risk through fewer needle insertions, convenience with simpler preparation and administration, and often better cost efficiency than purchasing separately.
Can BPC-157 and TB-500 be mixed together safely?
Yes. Both peptides are stable when combined in solution and can be reconstituted together without degradation or interaction. They maintain their individual activities when blended.
What ratio is used in this blend?
The standard research ratio is 1:1 by weight (5mg BPC-157 + 5mg TB-500). This ratio is most commonly referenced in combination research protocols.
Do I still need to dose differently for each peptide?
With the pre-blended format, a single dose delivers both peptides in the 1:1 ratio. This differs from using separate vials, where TB-500 is typically dosed less frequently (twice weekly) than BPC-157 (daily). The daily dosing of the blend provides consistent levels of both peptides.
How does dosing the blend compare to using separate peptides?
With separate peptides, typical protocols use BPC-157 at 250-500mcg daily and TB-500 at 2-2.5mg twice weekly (loading), then 2mg twice weekly (maintenance). With the blend, typical protocols use 250-500mcg of each daily from the combined product. The blend approach provides more consistent TB-500 levels through daily administration rather than twice-weekly peaks.
Is the combination better than either peptide alone?
Research suggests the combination may produce enhanced effects compared to either peptide individually due to complementary mechanisms. However, the specific application matters: localised injury with good blood supply may respond well to BPC-157 alone, systemic or multiple injuries may benefit from the combination, and injuries in poorly vascularised tissue (tendons, ligaments) may particularly benefit from the combination which addresses both blood supply (BPC-157) and cell delivery (TB-500).
What are the storage requirements for the blend?
Lyophilised (powder) form: stable at room temperature for weeks; refrigeration (2-8°C) extends stability to 6+ months; freezing (-20°C) extends stability to 12+ months. Reconstituted solution: must be refrigerated at 2-8°C; stable for 4-6 weeks when stored correctly. Do not freeze after reconstitution.
The Science: Why These Peptides Complement Each Other
Different Phases of Healing
Tissue healing involves multiple overlapping phases:
1. Inflammation Phase (Days 1-3)
- Both peptides modulate inflammation
- TB-500 reduces excessive inflammatory cytokines
- BPC-157 modulates nitric oxide and inflammatory signalling
2. Proliferation Phase (Days 3-21)
- TB-500 promotes migration of fibroblasts and endothelial cells
- BPC-157 promotes angiogenesis and growth factor expression
- New tissue formation requires both cell delivery AND repair activation
3. Remodelling Phase (Weeks to Months)
- Both contribute to organised collagen formation
- Better tissue architecture vs. disorganised scar tissue
Mechanistic Comparison
| Aspect | BPC-157 | TB-500 |
|---|---|---|
| Primary Target | VEGFR2, NO system | G-actin (cell structure) |
| Distribution | Strongest locally | Inherently systemic |
| Cell Migration | Indirect (via growth factors) | Direct (actin regulation) |
| Angiogenesis | Strong (primary mechanism) | Moderate (via cell migration) |
| Anti-inflammatory | Moderate | Strong |
| Typical Dosing | Daily | Twice weekly (alone) or daily (blend) |
| Origin | Gastric juice protein | Thymosin Beta-4 |
| Size | 15 amino acids | ~43 amino acids (active region) |
Why Not Just Higher Doses of One?
Increasing the dose of a single peptide eventually reaches diminishing returns and may increase side effects. The combination approach:
- Activates multiple independent pathways simultaneously
- May produce effects neither peptide achieves alone
- Addresses different healing bottlenecks
- Potentially allows lower doses of each while maintaining efficacy
Technical Specifications
| Property | BPC-157 | TB-500 | Blend |
|---|---|---|---|
| Amount | 5mg | 5mg | 10mg total |
| Ratio | - | - | 1:1 |
| Molecular Weight | 1419.53 Da | ~4963 Da | - |
| Amino Acids | 15 | ~43 (active region) | - |
| Primary Mechanism | VEGFR2/Angiogenesis | Actin/Cell Migration | Complementary |
| CAS Number | 137525-51-0 | 77591-33-4 | - |
| Appearance | White powder | White powder | White powder |
| Purity | ≥99% | ≥99% | ≥99% each |
| Storage (Powder) | -20°C | -20°C | -20°C |
| Storage (Reconstituted) | 2-8°C, 4-6 weeks | 2-8°C, 4-6 weeks | 2-8°C, 4-6 weeks |
Quality: Australian University Testing
Why Peptide Quality Matters
The research peptide market contains products of highly variable quality. Independent testing of products from various suppliers has revealed significant issues:
- Purity levels as low as 50% in products claiming "99% purity"
- Incorrect amino acid sequences (entirely wrong peptides)
- Truncated sequences (missing amino acids)
- Bacterial endotoxin contamination
- Oxidised or degraded peptides with reduced activity
Our Testing Protocol
Every batch of BPC-157 + TB-500 Blend from PurposeLabs undergoes comprehensive testing at a leading proteomics laboratory based at an Australian university in Sydney – one of Australia's premier analytical facilities.
Confirms purity levels of ≥99%, identifies any impurities or degradation products.
Verifies exact molecular weight, confirms correct amino acid sequence.
Determines actual peptide content versus salt, moisture, and counter-ions.
Why Australian University Testing?
Our testing partner is an established, verifiable proteomics facility at a major Australian university, with published research credentials, transparent methodology, and no commercial conflict of interest. This contrasts with overseas "certificates of analysis" from unknown or unverifiable laboratories.
Shop BPC-157 + TB-500 Blend
Australian university tested. 99%+ purity verified by HPLC and mass spectrometry. Fast shipping from Sydney.
| Product | Size | Price |
|---|
References
Key studies on the individual peptides and their mechanisms:
BPC-157 References
- Sikiric P, et al. "Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model." European Journal of Pharmacology, 1999.
- Hsieh MJ, et al. "Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation." Journal of Molecular Medicine, 2017.
- Seiwerth S, et al. "BPC 157's effect on healing." Journal of Physiology Paris, 2018.
TB-500 References
- Goldstein AL, et al. "Thymosin β4: actin-sequestering protein moonlights to repair injured tissues." Trends in Molecular Medicine, 2005.
- Bock-Marquette I, et al. "Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair." Nature, 2004.
- Malinda KM, et al. "Thymosin β4 accelerates wound healing." Journal of Investigative Dermatology, 1999.
Combination/Mechanism References
- Sosne G, et al. "Thymosin beta 4 promotes corneal wound healing and modulates inflammatory mediators in vivo." Experimental Eye Research, 2001.
- Sikiric P, et al. "Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications." Current Neuropharmacology, 2016.
Disclaimer
All products sold by PurposeLabs are intended for laboratory and research use only. They are not intended for human or animal consumption. The information provided is for educational purposes only and should not be construed as medical advice. Consult with qualified healthcare professionals for any health-related decisions.
BPC-157 + TB-500 Blend is not approved by the TGA for therapeutic use in Australia. Products are sold strictly for research purposes in accordance with Australian regulations.